TICKERNERD
Menu
MRKRMRKRHealthcare · Biotechnology

MRKR Stock Forecast: Marker Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$1.04
+2.97% on the day

The 3 Wall Street analysts covering Marker Therapeutics, Inc. hold a median 12-month price target of $8 — +669.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 7 Oct 2026 — in the upper half.

Market cap
$16.8M
Ticker Nerd rank
62 / 100
Median analyst target
$8.00
Analysts covering
3
Revenue$0.0
Operating income−$1.9M
Net income−$1.8M
Free cash flow−$3.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.8%
1M
−11.9%
YTD
−30.2%
1Y
−1.9%
From 52W high
−52.5%
From 52W low
+20.9%
$0.86
$2.19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MRKR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Marker Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Growth
87
Revisions
81
Volatility
62
Momentum
57
Value
49
Issuance
32
Accruals
23
Quality
19

Size (89): Smaller than most of the companies we track.

Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MRKR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MRKR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26MRKRHigh $10.00Median $8.00Low $5.60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $5.60Median $8.00High $10.00

The green dot is the last close — the median target sits +669.2% from it.

Recent analyst actionsNewest first

Of the 19 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
8 Dec 2025HC Wainwright & Co.InitiatesBuy$10
1 Apr 2025WBB SecuritiesReiteratesStrong Buy—
5 Mar 2025Canaccord GenuityInitiatesBuy—
21 Oct 2024Ladenburg ThalmannMaintainsBuy$11 → $19
30 Apr 2024Ladenburg ThalmannInitiatesBuy—
17 Feb 2022Roth CapitalDowngradeNeutral$3.00 → $1.00
25 Mar 2021Piper SandlerInitiatesOverweight—
19 Mar 2021Cantor FitzgeraldInitiatesOverweight—
18 Mar 2021Cantor FitzgeraldInitiatesOverweight—
12 May 2020Piper SandlerDowngradeNeutral$5.00 → $2.50
13 Nov 2019Janney CapitalMaintainsBuy—
13 Nov 2019Janney Montgomery ScottMaintainsBuy$15 → $10
13 Nov 2019Piper JaffrayMaintainsOverweight—
13 Nov 2019Piper SandlerMaintainsOverweight$10 → $6.00
3 July 2019OppenheimerInitiatesOutperform—
30 May 2019Roth CapitalInitiatesBuy—
29 Mar 2019WBB SecuritiesUpgradeStrong Buy—
1 Mar 2019Janney CapitalInitiatesBuy—
1 Mar 2019Janney Montgomery ScottInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MRKR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MRKR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Marker Therapeutics, Inc. returned −1.9% against +17.4% for the S&P 500, dividends included.

MRKR vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26MRKRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MRKR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Marker Therapeutics, Inc. (MRKR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 84% of US stocks

Price / sales
4.7×

Cheaper than 26% of US stocks

Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
−0.5×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−268.0%

Higher than 9% of US stocks

Net margin
−245.5%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−76.9%

Higher than 16% of US stocks

Return on assets
−40.5%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Marker Therapeutics, Inc. (MRKR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Marker Therapeutics, Inc. has a market value of $16.8M and an enterprise value of $5.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$8.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$9.8M.

  • Shares outstanding: 16.7M.

  • Trailing P/E: −1.3×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Marker Therapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

MRKR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MRKRMarker Therapeutics, Inc.$16.8M
62
ACTUActuate Therapeutics, Inc.$17.4M
35
ESLAEstrella Immunopharma, Inc.$17.6M
22
LPCNLipocine, Inc.$17.7M
43
TCRXTScan Therapeutics, Inc.$18.1M
53
DYAIDyadic International, Inc.$18.3M
17
ICUSeastar Medical Holding Corp.$16.4M
24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Marker Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MRKR news & analysis

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

GlobeNewsWire · 22 Sept 2026positive

Marker Therapeutics, Inc. highlighted the expanded infrastructure, technical expertise, and manufacturing capabilities supporting its lead program MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therapies. The company noted the strengthened CDMO support for its clinical-stage MAR-T cell therapy development.

Why it matters — MRKR watchers would care because enhanced manufacturing support from its CDMO partner strengthens the infrastructure behind its lead clinical program, MT-601.

FAQ

Frequently asked questions about MRKR stock

What is the MRKR stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Marker Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $5.6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MRKR stock a buy right now?

Of the 3 analysts covering Marker Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Marker Therapeutics, Inc. 62 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MRKR?

As at 7 Oct 2026, Marker Therapeutics, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will MRKR stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +669.2% from the last close, and Ticker Nerd's factor model ranks Marker Therapeutics, Inc. 62 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MRKR stock forecast for 2030?

No analyst covering Marker Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.6 to $10 over the next 12 months.

How has MRKR stock performed over the past year?

Marker Therapeutics, Inc. returned -1.9% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Marker Therapeutics, Inc. do?

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors.

What is the latest news on MRKR?

The most recent item we track (GlobeNewsWire, 22 Sept 2026): "Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies". Marker Therapeutics, Inc. highlighted the expanded infrastructure, technical expertise, and manufacturing capabilities supporting its lead program MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therapies. The company noted the strengthened CDMO support for its clinical-stage MAR-T cell therapy development.

Company

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors. Its core platform uses non-genetically engineered tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of creating broader anti-cancer activity. The company’s current pipeline includes product candidates such as MT-601, being studied in lymphoma and pancreatic cancer, and MT-401-OTS, being evaluated in acute myeloid leukemia and myelodysplastic syndromes. Marker Therapeutics also explores peptide-based vaccine approaches as part of its cancer treatment portfolio. Headquartered in Houston, Texas, the company operates in the biotechnology sector and serves the specialized area of cell therapy research and development, where its work supports the advancement of next-generation treatments for difficult-to-treat malignancies.

CEO Dr. Juan F. Vera M.D. · 5 employees · United States · https://markertherapeutics.com